Djurovic J, Stamenkovic G, Todorovic J, Aleksic N, Stojkovic O
Pajecki D, Halpern A, Cercato C, Mancini M, de Cleva R, Santo MA
Mochi Health: Specific Patient Profiles Who Should Avoid It (and Why) At a glance Service type / GLP-1 telehealth (insurance + cash-pay) Primary medications offered / Semaglutide, tirzepatide, compounded GLP-1 agents Monthly membership fee / Approximately $99/month (as of early 2025) Insurance accepted / Yes, select plans BBB accreditation / Not accredited as of January 2025 FDA-cleared drugs available / Yes (Wegovy, Ozempic, Mounjaro, Zepbound) Key contraindicated profiles / MTC/MEN2 history, active eating disorder, pregnancy, severe renal/hepatic disease LegitScript status / Not certified as of January 2025 Prescriber type / Physician and nurse practitioner-staffed asynchronous + synchronous visits Compounded GLP-1 risk / Compounded semaglutide from 503A/503B pharmacies carries FDA safety warnings What Is Mochi Health and How Does It Work

You will learn how pricing works, why costs vary, how mobile IV therapy compares to in clinic treatment and how dosage and treatment goals influence what you pay
This work was conducted independently of, and was not funded by GlaxoSmithKline K.K
So the surrounding protocol recommendations have more clinical support than the BPC-157 claim itself